89
Participants
Start Date
August 11, 2014
Primary Completion Date
December 28, 2021
Study Completion Date
April 4, 2022
Fludarabine
Cyclophosphamide
Leukapheresis
Cytokine-induced killer cells
IL-2
ALT-803
Peripheral blood for correlative studies
-Screening, Day 0 prior to CIML NK infusion, Day 1, Day 3, Day 7, Day 8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 60, Day 100, 6 months, 9 months, 12 months, and at disease relapse
Bone marrow for correlative studies
-Screening, Day 8, Day 14, Day 28, Between Day 42 and 60, Day 100, at disease relapse
Washington University School of Medicine, St Louis
Collaborators (1)
American Society of Clinical Oncology
OTHER
American Society of Hematology
OTHER
Gabrielle's Angel Foundation
OTHER
The Leukemia and Lymphoma Society
OTHER
National Cancer Institute (NCI)
NIH
ImmunityBio, Inc.
INDUSTRY
Washington University School of Medicine
OTHER